A systematic literature review and meta-analysis of randomized clinical trials of parenteral glutamine supplementation.

Study answer

What this study found

Parenteral glutamine reduced infectious complications and shortened hospital length of stay, but it did not significantly reduce short-term mortality overall. Pooled results showed mortality RR 0.89 (95% CI 0.77 to 1.04; p = 0.145), infections RR 0.83 (95% CI 0.72 to 0.95; p = 0.009), and hospital LOS MD = −2.35 days (95% CI −3.68 to −1.02; p = 0.001). Benefits were more apparent in some subgroup analyses at doses >0.20 g/kg BW/day and durations >9 days. The authors concluded that parenteral glutamine may help reduce morbidity, but its overall effectiveness in intensive care remains uncertain.

Study & population

Systematic review and meta-analysis of 40 randomized clinical trials in 3107 analyzable adults receiving parenteral nutrition in ICU or surgical settings.

Intervention

Parenteral glutamine was added to parenteral nutrition in randomized trials of critically ill and surgical adults.

Key limitation

Mortality was not significantly improved overall, and results were influenced by the SIGNET trial.

View full study detailsView sourceOpen PDF

Original abstract